We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+18.95%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.85B
AUM Growth
-$38.7M
(-1.3%)
Cap. Flow
-$602M
Cap. Flow
% of AUM
-21.14%
Top 10 Holdings %
Top 10 Hldgs %
27.89%
Holding
132
New
16
Increased
23
Reduced
29
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$55.3M |
| 2 |
Xeris Biopharma Holdings
XERS
|
+$48.6M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$41.7M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$27.9M |
| 5 |
Tandem Diabetes Care
TNDM
|
+$27.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$93.4M |
| 2 |
DexCom
DXCM
|
+$41M |
| 3 |
DaVita
DVA
|
+$32.1M |
| 4 |
GSK
GSK
|
+$31.6M |
| 5 |
Viatris
VTRS
|
+$31.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.94% |
| 2 | Financials | 2.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
26
DELISTED
Aerie Pharmaceuticals
AERI
| $32.7M | 1.15% |
484,055
| – | – |
|
|
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $32.5M | 1.14% |
233,000
+7,548
| +3% | +$1.07M |
|
28
Ascendis Pharma A/S
ASND
$17.1B
| $32.1M | 1.13% |
482,467
| – | – |
|
|
ECYT
29
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $32.1M | 1.13% |
2,324,299
-303,241
| -12% | -$3.6M |
|
|
WBA
30
DELISTED
Walgreens Boots Alliance
WBA
| $31.9M | 1.12% |
531,000
+175,000
| +49% | +$11.3M |
|
31
Glaukos
GKOS
$9.21B
| $30.7M | 1.08% |
754,222
-888,809
| -54% | -$31.6M |
|
32
Acadia Healthcare
ACHC
$3.17B
| $30.3M | 1.06% |
741,016
| – | – |
|
|
BPMC
33
DELISTED
Blueprint Medicines
BPMC
| $30.1M | 1.06% |
474,950
+96,000
| +25% | +$7.64M |
|
34
Agios Pharmaceuticals
AGIO
$2.36B
| $29.5M | 1.04% |
350,000
-16,000
| -4% | -$1.4M |
|
35
Universal Health Services
UHS
$9.15B
| $29.2M | 1.03% |
262,000
| – | – |
|
|
IMMU
36
DELISTED
Immunomedics Inc
IMMU
| $26.6M | 0.94% |
1,124,800
+194,352
| +21% | +$3.91M |
|
|
DFBHU
37
DELISTED
DFB Healthcare Acquisitions Corp. Unit
DFBHU
| $25.4M | 0.89% |
2,500,000
| – | – |
|
|
MLNT
38
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
| $25.4M | 0.89% |
799,161
+173,592
| +28% | +$6.25M |
|
|
LCI
39
DELISTED
Lannett Company, Inc.
LCI
| $24.5M | 0.86% |
450,338
-234,931
| -34% | -$14.8M |
|
40
eHealth
EHTH
$47.3M
| $24.4M | 0.86% |
1,104,952
+74,150
| +7% | +$1.43M |
|
|
EPZM
41
DELISTED
Epizyme, Inc
EPZM
| $22.2M | 0.78% |
1,639,000
+678,030
| +71% | +$10.6M |
|
42
Rhythm Pharmaceuticals
RYTM
$7.31B
| $22M | 0.77% |
703,600
+121,590
| +21% | +$3.32M |
|
|
RETA
43
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $21.3M | 0.75% |
609,554
+219,554
| +56% | +$6.69M |
|
44
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $21.3M | 0.75% |
+1,226,890
| New | +$22.2M |
|
45
Brookdale Senior Living
BKD
$3.58B
| $21M | 0.74% |
+2,305,773
| New | +$17.9M |
|
46
Natera
NTRA
$38.9B
| $20.3M | 0.71% |
1,080,829
-2,099,171
| -66% | -$25.5M |
|
|
MOR
47
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $18.2M | 0.64% |
+600,000
| New | +$16.5M |
|
|
AIMT
48
DELISTED
Aimmune Therapeutics
AIMT
| $18.1M | 0.64% |
673,000
-37,210
| -5% | -$1.14M |
|
|
CBAY
49
DELISTED
Cymabay Therapeutics
CBAY
| $18M | 0.63% |
1,343,181
+130,000
| +11% | +$1.63M |
|
|
BLUE
50
DELISTED
bluebird bio
BLUE
| $17.7M | 0.62% |
8,724
+5,559
| +176% | +$12.7M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2018 Portfolio in Review
As of Q2 2018, Deerfield Management held 132 positions worth $2.85B, down 1.3% from $2.89B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Deerfield Management withdrew a net $602M in Q2 2018, closing 17 positions and reducing 29 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $93.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Portola Pharmaceuticals, Inc. worth $54.6M.
- Deerfield Management's largest Q2 2018 buy was Portola Pharmaceuticals, Inc.: 1,446,633 shares worth $54.6M.
- Deerfield Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2018, an estimated $41.7M increase.
- Deerfield Management's biggest Q2 2018 reduction was DexCom, cutting an estimated $41M.
- Deerfield Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $93.4M.
- Deerfield Management's ten largest holdings make up 28% of its $2.85B portfolio in Q2 2018.
- Deerfield Management opened 16 new positions and closed 17 in Q2 2018.
- Deerfield Management's portfolio value fell 1.3% quarter-over-quarter to $2.85B.
Based on Deerfield Management's 13F filing for Q2 2018, filed 14 Aug 2018.